1.Progress in treatment of childhood Hodgkin lymphoma.
Yan-Long DUAN ; Yong-Hong ZHANG
Chinese Journal of Hematology 2011;32(8):567-571
Child
;
Hodgkin Disease
;
therapy
;
Humans
3.Recent research progress in Gaucher disease.
Yan-long DUAN ; Yong-hong ZHANG
Chinese Journal of Pediatrics 2009;47(12):953-955
4.Content Determination of Schisandrin in Hugan Pill by HPLC
Zeheng ZHANG ; Haiyan LONG ; Yong ZHAO
Chinese Journal of Information on Traditional Chinese Medicine 2006;0(12):-
Objective To develop the method for determining the content of Schisandrin by HPLC. Method The Schisandrin in Hugan Pill was determinined by HPLC. The analytical column was Hanbon Lichrospher (250 mm?4.6 mm, 5 ?m) and mobile phase was methanol-water (67∶33), with wavelength was set at 251 nm. Result Schisandrin had good linear relationship with their peak area in the range of 0.105 1~2.102 ?g (r=0.999 9, n =7). The average recovery rate was 97.03%, RSD was 1.02% (n =5). Conclusion The method was rapid, simple and precise.
5.Expression of WWOX protein and its significance in non-small cell lung cancers.
Yu-long ZHOU ; Yong-jian XU ; Zhen-xiang ZHANG
Chinese Journal of Oncology 2007;29(4):297-297
Adenocarcinoma
;
metabolism
;
pathology
;
Adult
;
Aged
;
Carcinoma, Non-Small-Cell Lung
;
metabolism
;
pathology
;
Carcinoma, Squamous Cell
;
metabolism
;
pathology
;
Female
;
Humans
;
Immunohistochemistry
;
Lung
;
chemistry
;
pathology
;
Lung Neoplasms
;
metabolism
;
pathology
;
Male
;
Middle Aged
;
Oxidoreductases
;
metabolism
;
Sex Factors
;
Smoking
;
Tumor Suppressor Proteins
;
metabolism
;
WW Domain-Containing Oxidoreductase
6.Analysis on public-private partnerships and implications for China:Cases of Brazil, South Af-rica, and India
Long CHEN ; Lei FENG ; Ruihong ZHANG ; Yong MAO ; Kai WANG
Chinese Journal of Health Policy 2014;(12):9-14
Around the world, the supply of health services faces challenges, especially in developing nations that suffer from inadequate infrastructure and aging equipment, frequent shortages of medicine and supplies, and low capacity and efficiency of primary health care. At present, more and more governments adopt public-private partner-ships to achieve public policy goals. Among those, Brazil, South Africa, and India have made greater achievements in changing the roles of local government, increasing the supply of primary health care and health care quality, pro-moting health care equality, meeting the needs of multi-level medical services, and promoting health capabilities by using public-private partnerships. This paper provides an overview of public-private partnership practices in the three countries, discusses their reform experiences, and concludes with implications which may be helpful for promoting and scaling up PPP in primary health care in China.
8.Misdiagnosis Analysis of 31 Cases with Anaplastic Large Cell Lymphoma in Children
jing, YANG ; yong-hong, ZHANG ; yan-long, DUAN
Journal of Applied Clinical Pediatrics 2006;0(15):-
Objective To make clinical doctors better understanding of anaplastic large cell lymphoma(ALCL) and reduce the misdiagnosis of ALCL at an earlier stage.Methods Retrospective analysis of clinical features in 31 children with ALCL from Sep.2002 to Jan.2008,who had been misdiagnosed as other diseases at first and latterly been confirmed as ALCL by pathological study.The reasons for mis-diagnosis and the symptoms of the disease were analyzed and reviewed.Results ALCL clinical misdiagnosis rate reached to 91.2%.The reasons for misdiagnosis were:1.The fact that extra-nodal involvement present in earlier stage,which caused ALCL to have diversified clinical symptoms,and the initial symptoms were diverse.2.ALCL cells produce multiple cytokines such as IL-6,IL-9,IL-4,and others.They might make patients have symptoms like inflammation.3.The morphology of ALCL was quite variable.4.The clinical doctors and pathologists did not have frofound understandings of ALCL.5.Inapropriate usage of steroid before diagnosis was mode.Conclusions Clinical doctors should be aware of the diversity of ALCL clinical symptoms and use steroid carefully,while pathologists should pay attention to morphological varieties of ALCL and choose appropriate immunohistiochemical stain markers to avoid misdiagnose.Pathologic diagnosis should be made by more than 2 oncology centers.
9.The optimal liquid-to-air ratio for the preparation of 1% lauromacrogol foam sclerosant
Long LI ; Di ZHANG ; Xinqiao ZENG ; Qingle ZENG ; Yong CHEN
Journal of Interventional Radiology 2015;(5):418-421
Objective To investigate the stability of 1% lauromacrogol foam sclerosant prepared with different liquid-to-air ratio in order to find out the optimal liquid-to-air ratio. Methods According to Tessari technique, two 10 ml disposable plastic syringes and one three-way plastic stopcock were used to mix 1%lauromacrogol with room air, and liquid-to-air ratios from 1∶1 to 1∶9 were separately employed to make the preparation of the foam sclerosant. Each kind of liquid-to-air ratio was used to separately make bubbles for 5 times, the foam half-life time (FHT), the foam drainage time (FDT) and the foam coalescence time (FCT) were recorded, and their mean values were calculated. The optimal liquid-to-air ratio was defined as the intermediate values of all the above measured indexes. Results When the liquid-to-air ratio was 1 ∶ 1, 1 ∶2, 1 ∶ 3, 1 ∶ 4, 1 ∶ 5, 1 ∶ 6, 1 ∶ 7, 1 ∶ 8 and 1 ∶ 9, the FHT of 1% lauromacrogol foam sclerosant was 184.8, 169.3, 135.9, 110.8, 111.5, 92.6, 76.3, 74.7 and 49.9 seconds respectively; the FDT was 10.6, 17.8, 14.6, 13.7, 13.0, 12.3, 10.7, 11.5 and 12.6 seconds respectively; while the FCT was 108.4, 79.8, 41.8, 20.3, 10.4, 0, 0, 0 and 0 seconds respectively. Conclusion Based on Tessari technique, the indoor air, two 10 ml disposable plastic syringes and one three-way plastic stopcock are used to prepare 1%lauromacrogol foam sclerosant, and the optimal liquid-to-air ratio is 1 ∶ 2.
10.Clinical study on the efficacy and safety of composite milk clotting enzyme capsules in children with functional dyspepsia
Cuiping LIANG ; Shaoming ZHOU ; Xiaoling LONG ; Yong ZHANG ; Sitang GONG
Chinese Journal of Applied Clinical Pediatrics 2014;29(19):1447-1450
Objective To evaluate the efficacy and safety of composite milk clotting enzyme capsules in children with functional dyspepsia.Methods A multicenter,randomized,open-label clinical trial was carried out in 4Guangzhou hospitals during Feb.2012 to Mar.2013.Children with functional dyspepsia on basis of Rome Ⅲ criteria were enrolled and treated with composite milk clotting enzyme capsules.Total symptom score and drug-related adverse reactions were evaluated after one-week and two-week therapy.The treatment outcome were divided into very effective,fairly effective and ineffective according to the symptom score changes.Superiority test was done for effectiveness of the treatment based on efficacy difference by 10% regarded as superiority.Results Two hundred and one children were enrolled.One hundred and ninety-six children completed the study as planned.After two-week therapy,better effective rate and total effective rate were 68.88% and 87.76%,higher than those of one-week therapy (27.04%,76.02%) (U =2.935,P < 0.05).The lower limits of 95 % confidence interval of difference in symptoms improve rate,better efficacy rate and symptom score decrease rate between two-week and one-week therapy were more than 10%,and two-week therapy was superior to one-week therapy.No significant drug-related adverse reaction was found during the study.Conclusions Composite milk clotting enzyme capsules can improve functional dyspepsia symptoms significantly.The effectiveness of two-week of treatment is better than that of one-week treatment.No obvious drug-related adverse reaction is observed.